Onxeo Changes Its Name and Becomes Valerio Therapeutics Following Approval by the Annual General Mee

All the resolutions approved by the Board of Directors were adoptedPARIS--(BUSINESS WIRE)--Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and dr...

Related Keywords

Paris ,France General ,France ,Robert Coleman ,Nicolas Trebouta ,Nicolas Fossiez ,Arthur Rouill ,Shefali Agarwal ,Onxeo Sa Euronext ,Company Group ,Regulatory News ,Euronext Growth Paris ,Annual General Meeting ,Valerio Therapeutic ,Chief Executive Officer ,General Meeting ,General Meetings ,